NCT01349296View on ClinicalTrials.gov

BIBF 1120 and RAD001 in Solid Tumors - Phase I

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

May 31, 2016

Conditions
Solid Tumors
Interventions
DRUG

Everolimus + BIBF 1120

Dose level 1: 1x 5mg Everolimus/d + 2x 150mg BIBF 1120/d. Dose level 2: 1x 5mg Everolimus/d + 2x 200mg BIBF 1120/d. Dose level 3: 1x 10mg Everolimus/d + 2x 200mg BIBF 1120/d

Trial Locations (1)

50937

University Hospital of Cologne, Cologne

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

University of Cologne

OTHER

NCT01349296 - BIBF 1120 and RAD001 in Solid Tumors - Phase I | Biotech Hunter | Biotech Hunter